<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8<sup>+</sup> T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma by Blümel, Edda et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells
in cutaneous T-cell lymphoma
Blümel, Edda; Munir Ahmad, Shamaila; Nastasi, Claudia; Willerslev-Olsen, Andreas; Gluud,
Maria; Fredholm, Simon; Hu, Tengpeng; Surewaard, Bas G.J.; Lindahl, Lise M.; Fogh,
Hanne; Koralov, Sergei B.; Rahbek Gjerdrum, Lise Mette; Clark, Rachael A.; Iversen, Lars;
Krejsgaard, Thorbjørn; Bonefeld, Charlotte Menné; Geisler, Carsten; Becker, Jürgen C.;
Woetmann, Anders; Andersen, Mads Hald; Buus, Terkild Brink; Ødum, Niels
Published in:
OncoImmunology
DOI:
10.1080/2162402X.2020.1751561
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Blümel, E., Munir Ahmad, S., Nastasi, C., Willerslev-Olsen, A., Gluud, M., Fredholm, S., ... Ødum, N. (2020).
Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell
lymphoma. OncoImmunology, 9(1), [1751561]. https://doi.org/10.1080/2162402X.2020.1751561
Download date: 23. Jun. 2020
OncoImmunology
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/koni20
Staphylococcus aureus alpha-toxin inhibits CD8+ T
cell-mediated killing of cancer cells in cutaneous T-
cell lymphoma
Edda Blümel , Shamaila Munir Ahmad , Claudia Nastasi , Andreas Willerslev-
Olsen , Maria Gluud , Simon Fredholm , Tengpeng Hu , Bas G. J. Surewaard ,
Lise M. Lindahl , Hanne Fogh , Sergei B. Koralov , Lise Mette Rahbek
Gjerdrum , Rachael A. Clark , Lars Iversen , Thorbjørn Krejsgaard , Charlotte
Menné Bonefeld , Carsten Geisler , Jürgen C. Becker , Anders Woetmann ,
Mads Hald Andersen , Terkild Brink Buus & Niels Ødum
To cite this article: Edda Blümel , Shamaila Munir Ahmad , Claudia Nastasi , Andreas Willerslev-
Olsen , Maria Gluud , Simon Fredholm , Tengpeng Hu , Bas G. J. Surewaard , Lise M. Lindahl ,
Hanne Fogh , Sergei B. Koralov , Lise Mette Rahbek Gjerdrum , Rachael A. Clark , Lars Iversen ,
Thorbjørn Krejsgaard , Charlotte Menné Bonefeld , Carsten Geisler , Jürgen C. Becker , Anders
Woetmann , Mads Hald Andersen , Terkild Brink Buus & Niels Ødum (2020) Staphylococcus
aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell
lymphoma, OncoImmunology, 9:1, 1751561, DOI: 10.1080/2162402X.2020.1751561
To link to this article:  https://doi.org/10.1080/2162402X.2020.1751561
© 2020 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 17 Apr 2020.
Submit your article to this journal 
Article views: 377
View related articles 
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20
View Crossmark data
BRIEF REPORT
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ABSTRACT
Staphylococcus aureus and its toxins have been linked to disease progression and mortality in advanced
stages of cutaneous T-cell lymphoma (CTCL). CD8+ T cells play a crucial role in anti-cancer responses and
high CD8+ T cell numbers in tumor lesions are associated with a favorable prognosis in CTCL. Here, we
show that CD8+ T cells from both healthy donors and Sézary syndrome patients are highly susceptible to
cell death induced by Staphylococcal alpha-toxin, whereas malignant T cells are not. Importantly, alpha-
toxin almost completely blocks cytotoxic killing of CTCL tumor cells by peptide-specific CD8+ T cells,
leading to their escape from induced cell death and continued proliferation. These findings suggest that
alpha-toxin may favor the persistence of malignant CTCL cells in vivo by inhibiting CD8+ T cell cytotoxi-
city. Thus, we propose a novel mechanism by which colonization with Staphylococcus aureus may
contribute to cancer immune evasion and disease progression in CTCL.
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Introduction
Cutaneous T-cell lymphoma (CTCL) is a family of non-
Hodgkin lymphomas characterized by the accumulation of
malignant CD4+ T cells in the skin.1 Mycosis fungoides
(MF) is the most common form of CTCL, characterized by
inflamed skin lesions with a complex microenvironment.1–3
Primary CD30+ lymphoproliferative disorders (LPD) are
the second largest subtype of CTCL and Sézary syndrome
(SS) is a highly aggressive leukemic variant of the disease.1
CTCL is associated with a compromised skin barrier, bacterial
colonization, and subsequent infections, which are a major cause
of morbidity and mortality in advanced disease stages.4,5 Bacteria
have also been shown to promote disease progression in a mouse
model of CTCL.6 The pathogen most frequently found to be
associated with CTCL is Staphylococcus aureus (S. aureus).7
S. aureus releases a variety of toxins, including super-antigens,
which have been proposed to play an important role in CTCL
progression.8–10 Another important toxin produced by S. aureus is
the pore forming alpha-toxin, also known as alpha-hemolysin and
hla, which is known to induce cell death in T cells.11 Alpha-toxin
production correlates both with Staphylococcal virulence in ani-
mal infection models and disease severity in humans.12,13 Alpha-
toxin is expressed by the majority of S. aureus strains and has
shown to be produced by clinical isolates from CTCL lesions.14
We have recently shown that, in contrast to healthy CD4+ T cells,
malignant T cells are relatively resistant to cell death induced by
alpha-toxin.15 However, the effect of alpha-toxin on CD8+ T cells
from CTCL patients, the impact of this toxin on anti-tumor
responses and its potential pathogenic role in the disease has not
been investigated.
Antigen-specific CD8+ T cells play an important role in
immune surveillance and the defense against cancer. Upon
activation, CD8+ T cells differentiate into cytotoxic
T lymphocytes (CTLs) that can specifically lyse transformed
cells in an MHC class I restricted manner. Malignant cells in
cancer are known to acquire various immune evasion
mechanisms that subvert CTL function. The observed pre-
sence of CTLs with the potential to kill autologous tumor cells
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in CTCL and the finding that high numbers of CD8+ T cells
have been linked to a favorable prognosis, have sparked the
hypothesis that CD8+ T cells are important in controlling the
early indolent stages of the disease and in preventing disease
progression.16,17 It has become clear that malignant T cells
display ectopic expression of numerous cancer associated
antigens such as embryonic stem cell and meiosis-specific
antigens, suggesting that these cancer-associated neo-
epitopes may play an important role in immune surveillance
by CD8+ T cells.18–20
In this study, we report that primary CD8+ T cells from SS
patients and healthy donors are potently killed by alpha-toxin,
whereas malignant cells are largely resistant. In addition, we show
that the presence of alpha-toxin dramatically inhibits peptide-
specific CD8+ T cell lysis of CTCL cells, allowing for continued
malignant proliferation. To our knowledge, this is the first study
to demonstrate that S. aureus alpha-toxin can block CD8 cyto-
toxicity and thus potentially facilitate cancer immune evasion.
Materials and methods
Cell culture and isolation of peripheral blood
mononuclear cells (PBMCs)
Peptide specific CD8+ T cells targeting MART-1, PD-L1 and
FOXP3 were all maintained in X-VIVO media (Lonza, #BE02-
060F) supplemented with 5% Human serum (HS) (Copenhagen
Hospital Blood Bank) and 2 × 103 U/ml IL-2 (Novartis,
#004184). All CD8+ T cell lines were established from HLA-A2
positive melanoma or breast cancer patients.21–24 Mac1 and
Mac2a cell lines were derived from a patient suffering from
a primary CD30+ LPD, manifesting as anaplastic large-cell lym-
phoma andMF, respectively.25,26 Both cell lines were maintained
in Roswell Park Memorial Institute (RPMI) 1640 medium
(Sigma-Aldrich, #R204), supplemented with 10% Heat inacti-
vated fetal bovine serum (FBS) (Biological Industries, #04-007-
1A) and 1% penicillin-streptomycin (Sigma, #P7539). Cells cul-
tures used were mycoplasma tested using the MycoAlertTM
PLUS Mycoplasma Detection Kit (Lonza, #LZ-LT07-710) and
MycoAlertTM Assay Control Set (Lonza, #LT07-518). Cells were
tested after thawing and experiments were only performed if
negative for mycoplasma. CD8+ T cells were grown for maximal
two weeks, while Mac1 and Mac2a cell lines were kept for up to
four weeks in culture until the last experiment was performed.
PBMCs from healthy donors and SS patients were obtained in
accordance with the Declaration of Helsinki. After approval by
the Committee on Health Research Ethics (H-16025331), writ-
ten informed consent was obtained from all SS patients
(Supplementary Table 1 patient characteristics). PBMCs were
isolated by Ficoll-based density-gradient centrifugation. Positive
selection of CD8+ T cells was performed using CD8MicroBeads
(Miltenyi Biotec, #130-045-201) and LS columns (Miltenyi
Biotec, #130-041-306) following the manufacturer’s instructions.
Alpha-toxin treatment
Purified alpha-toxin was obtained from List Biological
Laboratories (#120). Cells were treated with alpha-toxin at
37°C for the duration and with concentrations as stated in
the respective figures and figure legends.
LDH activity assay
Cells were grown in RPMI 1640 (Gibco, #11835-063) or
X-VIVO (Lonza, #BE02-061Q) media without phenol red prior
to measuring Lactate Dehydrogenase (LDH) release with the
LDH Cytotoxicity Detection Kit (TaKaRa, #MK401). LDH
release was quantified from culture supernatants following the
manufacturer’s instructions. Values were normalized to max
release measured in Triton X-100 treated samples prior to sub-
tracting the background absorbance.
Flow cytometry
Cell surface staining was performed in FACS-PBS (PBS + 1%
FBS + 0.02% NaN3) or Brilliant Stain Buffer (BD Bioscience,
#563794), using primary conjugated antibodies (listed in supple-
mentary Table 2). Malignant cells were gated as
CD3+CD4+TCRVβ#+ followed by subsequent exclusion of
CD26+CD7+ cells. In patients where the dominant TCRVβ
clone could not be targeted, malignant cells were gated as
CD3+CD4+CD7− and/or CD26−, as previously described.27
Intracellular staining with FOXP3-APC (eBioscience, #17-
4777-42) was performed using the eBioscience FOXP3/
Transcription Factor Staining Buffer Set (ThermoFisher, #00-
5523-00). Dead cells were excluded using propidium iodide
(eBioscience, #MBS500PI) and/or Annexin V-FITC/PE
(BioLegend, #640945/#640908) or Fixable Viability Dye
eFluor780 (eBiosciences, #65-0865-14). Annexin V staining
was conducted in Annexin V Binding Buffer (BD Bioscience,
#556454).
Peptide specificity of CD8+ T cells was quantified with
HLA-A2 tetramers. Cells were incubated with PE and APC
conjugated tetramer complexes (MART-1, PD-L1, FOXP3)
for 20 minutes at 37°C prior to cell surface and viability
staining. HIV tetramers were included as negative controls.
All flow cytometric analyses were performed using a 3 or 5
laser BD LSR-Fortessa. Flow cytometry data were visualized
and analyzed using FlowJo (TreeStar) software.
Co-culture
Peptide specific CD8+ T cells and Mac1/Mac2a cells were
labeled with CellTrace Blue (ThermoFisher, #C34574) and
CellTrace Violet (ThermoFisher, #C34557), respectively. In
short cells were washed in PBS, re-suspended in 0.5 ml PBS
containing 0.2% HS and 0.5 ml PBS containing 10 µM of the
respective dye were added. Cells were incubated for 5 minutes
at room temperature before staining was halted by addition of
10 ml X-VIVO media containing 10% HS. After 5 minutes of
incubation, cells were spun down and re-suspended in com-
plete culture media. Effector cells were treated with alpha-
toxin and target cells were pulsed with 1 nM of peptide for
2 hours at 37°C when indicated. Effector and target cells were
co-cultured for 4 hours at 37°C analyzed by flow cytometry
(gating strategy Supplementary Figure 1).
e1751561-2 E. BLÜMEL ET AL.
Proliferation was measured using 5-ethynyl-2`-deoxyiridine
(EdU) incorporation. EdU was added to the co-culture 24 hours
before analysis. Click-iT Plus EdU Alexa Fluor 488 assay
(ThermoFisher, #C10632) was performed following the manu-
facturer’s instructions with the modification of substituting the
provided fixative with the BD Cytofix/Cytoperm (BD
Bioscience, #554722).
Results
First, we determined whether CD8+ T cells were sensitive to
alpha-toxin-induced cell death. We exposed CD8+ T cells
from healthy donors and SS patients to alpha-toxin and ana-
lyzed toxin-induced cell death by LDH release assay and/or
flow cytometry. Regardless of the source, CD8+ T cells were
highly susceptible to alpha-toxin, while the malignant CTCL
cell line MyLa2059 was resistant (Figure 1(a–d)). Similarly,
primary malignant T cells from SS patients were more resis-
tant to alpha-toxin than the CD8+ T cells from the same
patient (Figure 1(e)). Hence, exposure to alpha-toxin drasti-
cally increased the ratio of malignant to CD8+ T cells in eight
of the ten tested SS patients (Figure 1(e)).
The difference in sensitivity between malignant CTCL
cells and CD8+ T cells suggested that alpha-toxin producing
S. aureus within the tumor microenvironment could abro-
gate tumor-specific CD8+ T cell responses toward malignant
CTCL cells. To test this, we first used a well-established
MART-1 peptide-based model to study MART-1 specific
CD8+ T cell-mediated killing of MART-1 pulsed cancer
cells (described in23). The strength of this anti-tumor CD8+
T cell cytotoxicity assay is that it is highly specific and
robust. Presentation of the MART-1 peptide to CD8+
T cells is restricted to HLA-A2 molecules and we only
observed specific killing of MART-1 pulsed HLA-A2+ Mac-
1 cell lines, but not of MART-1 pulsed HLA-A2- CTCL lines
such as MyLa2059.23 Accordingly, we pulsed Mac1 cells with
MART-1 peptide and co-cultured them with HLA-A2
restricted MART-1 specific CD8+ T cells that were pre-
Figure 1. CD8+ T cells are sensitive to alpha-toxin-induced cell death at concentrations where malignant CTCL cells are not. Malignant CTCL cells and CD8+ T cells
from healthy donors or SS patients were exposed to alpha-toxin for 6 hours at 37°C. Viability was assessed by flow cytometry and LDH release was measured in the
culture supernatant. (a) Schematic hypothesis for alpha-toxin favoring malignant cells over CD8+ T cells. (b,c) Purified primary CD8+ T cells from healthy donors and
the malignant CTCL cell line, MyLa2059 (n = 3). (d) CD8+ T cells from SS patients (n = 10). (e) Change in Malignant SS cells to CD3+CD8+ T cell ratio (n = 10) by alpha-
toxin exposure relative to untreated control. Line and bar plots display mean ± standard error of mean. Paired students t-tests using GraphPad Prism version 7.00. *
p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.
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treated with alpha-toxin or vehicle as a control. Specific
cytotoxicity was determined by LDH release and flow cyto-
metric analysis of remaining Mac1 cells. We found that pre-
treatment with alpha-toxin strongly inhibited CD8+ T cell-
mediated killing of MART1-pulsed malignant T cells
(Figure 2(a–d), Supplementary Figure 2(a,b)).
Figure 2. Alpha-toxin inhibits anti-cancer responses of peptide specific CD8+ T cells. Peptide specific CD8+ T cells were cultured for 2 hours at 37°C in the presence or absence of
alpha-toxin before being co-cultured for 4 hours with their respective target cells. (a) Schematic hypothesis of effect of alpha-toxin in co-cultures of CD8+ T cell effector cells and
target CTCL cells. B-D: MART-1 specific CD8+ T cells (n = 2). (b) LDH release after co-culture of MART-1 specific CD8+ T cells with MART-1 peptide pulsed Mac1 cells. Specific cell
lysis was calculated after subtracting the background release from both effector and target cells. (c) Normalized percentage of remaining target cells after exposure to MART-1
specific CD8+ T cells. (d) Tetramer staining of MART-1-specific CD8+ T cells. E-G: PD-L1 specific CD8+ T cells (n = 3). (e) Mac1 cells remaining after co-culture with PD-L1 specific
CD8+ T cells. (f) PD-L1 expression of Mac1 cells. The dashed line representing the expression levels of the FMO control. (g) Tetramer staining of PD-L1-specific CD8+ T cells. H-J:
FOXP3 specific CD8+ T cells (n = 3). (h) Displaying normalized percentage of Mac2a cells remaining after the exposure to FOXP3-specific CD8+ T cells. (i) Foxp3 expression of
Mac2a cells. The dashed line represents the expression levels of the isotype control. (j) Tetramer staining of FOXP3-specific CD8+ T cells. Bar plots display mean ± standard error
of mean. Paired students t-tests using GraphPad Prism version 7.00. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.
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Next, we addressed whether alpha-toxin inhibits CD8+ T cell-
mediated cytotoxicity against endogenous antigens expressed by
malignant T cells in CTCL. To this end, we utilized HLA-A2
restricted CD8+ T cells recognizing peptides derived from
Programmed cell death 1 ligand (PD-L1) or Forkhead box P3
(FOXP3), both representing peptides frequently found to be
dysregulated in CTCL.28–30 Similar to the inhibition of cytotoxi-
city in the MART-1 model, peptide-specific CD8+ T cells target-
ing endogenous CTCL peptides showed similar decrease in their
specific killing when cultured in the presence of alpha-toxin
(Figure 2(e–j) and Supplementary Figure 2(c–f)).
Finally, we wanted to investigate if the presence of alpha-
toxin could facilitate immune evasion by eliminating cancer-
specific CD8+ T cells, while allowing continued CTCL cell
proliferation. We co-cultured MART-1 peptide-pulsed Mac1
cells with MART-1 specific CD8+ T cells in the presence or
absence of alpha-toxin and measured the proliferation of
malignant target cells using flow cytometry (Figure 3(a)). In
the presence of alpha-toxin, peptide-pulsed malignant CTCL
cells continued to proliferate when co-cultured with CTLs,
whereas proliferation was almost completely abrogated when
co-cultured with reactive CTLs in the absence of alpha-toxin
(Figure 3(b–d)).
Discussion
Bacterial infections are a major cause of morbidity and mor-
tality in advanced stage CTCL.4 Notably, several lines of
evidence suggest that S. aureus fuels disease progression in
this malignant disease, although the underlying mechanism is
only partially understood.8 We have previously shown that
malignant CD4+ T cells are relatively resistant to alpha-toxin-
induced cell death compared to their nonmalignant CD4+
T cell counterparts.15 This suggests that alpha-toxin released
during staphylococcal infections may tilt the balance between
malignant and nonmalignant CD4+ T cells, favoring the per-
sistence of malignant cells in CTCL.
In this study, we demonstrate that CD8+ T cells are highly
sensitive toward alpha-toxin-induced toxicity, and that alpha-
toxin selects for malignant cells in the majority of the investi-
gated SS patients. Furthermore, we show that alpha-toxin effec-
tively inhibits CD8+ T cell-mediated anti-cancer responses,
while allowing malignant CTCL cells to persist and proliferate.
This was the case irrespective of whether peptide specific CD8+
T cells were directed against MART-1 or PD-L1 and FOXP3
peptides, which are endogenously expressed in CTCL. The cur-
rent study focused on the direct effect of alpha-toxin on
Figure 3. Alpha-toxin facilitates immune evasion and allows continued malignant proliferation. (a) Schematic hypothesis of alpha-toxin mediated immune evasion.
Target CTCL (Mac1) cells and effector CD8+ T cells were pre-treated with alpha-toxin or vehicle control before being co-cultured for 48 hours. During the last 24 hours
EdU was added to the culture. (b–d) Percentage and number of proliferating EdU+ Mac1 cells after 48 hours of co-culture with MART-1 specific CD8+ T cells (n = 3).
Both target and effector cells were pre-treated with 2-fold increasing concentrations of alpha-toxin. (b) Representative flow cytometry contour plot. (c) Percentage of
EdU+ target cells. (d) Number of EdU+ target cells. Bar and line plots depict mean ± standard error of mean for three independent replicates.
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cytotoxic CD8+ T cells using cell lines and primary cells isolated
from the blood of ten SS patients. Thus, our results do not
directly address whether similar effects occur in the skin of
S. aureus infected patients. While we have previously shown
that cell lines from various subtypes of CTCL are all resistant
to alpha-toxin induced cell death,15 this study was limited to
primary cells from SS patients and CD30+ LPD (Mac1 and
Mac2a) cell lines. These cell lines were chosen as they have
been previously used in CD8+ T cell mediated cytotoxicity assays
targeting exogenous or CTCL-relevant endogenous
peptides.21–24
High numbers of CD8+ T cells are significantly correlated
with increased survival in CTCL, suggesting that CD8+ T cells
are actively involved in restraining malignant cells.16,31
Indeed, CTCL patients harbor cytotoxic T cells with the
potential to kill autologous cancer cells in an HLA-Class
I restricted manner.17 The present findings outline a novel
mechanism whereby S. aureus infections can contribute to
immune evasion in CTCL through the release of alpha-
toxin. As shown here and elsewhere,15 we observed inhibitory
effects of alpha-toxin on primary CD4+ and CD8+ T cells at
concentrations above 0.1 μg/ml and maximal effects at around
1.5 μg/ml. However, little is known about the physiological
concentrations of alpha-toxin within lesional skin of CTCL
patients. Of notice, alpha-toxin concentrations in superna-
tants from community-associated alpha-toxin producing
S. aureus isolated from nasal swabs of colonized individuals
can vary between 1–60 μg/ml (mean of 40 μg/ml). Although
these figures cannot be extrapolated to concentrations in situ,
they suggest that the profound effects reported here at alpha-
toxin concentrations of 0.75–1.50 μg/ml are likely well within
the physiologically relevant range that we can expect in the
tumor micro-environment of CTCL skin lesions.32 Thus, our
findings suggest that environmental factors such as staphylo-
coccal toxins may directly interfere with anti-cancer responses
and facilitate disease progression. As such, alpha-toxin could
be a potential target for future therapies by vaccination or
neutralizing antibodies. Encouragingly, a neutralizing anti-
body targeting alpha-toxin (MEDI4893) has been shown to
be effective against S. aureus infection in a murine dermone-
crosis model and is currently being evaluated in clinical trials
of ventilator-associated pneumonia patients.12 However, the
effect of neutralizing alpha-toxin in CTCL patients has not yet
been tested.
IL-17 family cytokines are expressed in skin lesions in
a substantial fraction of CTCL patients and are associated with
progressive disease and poor prognosis.33,34 However, it is
unknown whether or not IL-17 family members play
a pathogenic role in disease progression.35 IL-17 cytokines are
an important part of host T helper 17 responses against
S. aureus in healthy individuals (reviewed in 36). Likewise,
S. aureus toxins trigger STAT3 mediated IL-17 expression in
cultures of primary malignant and nonmalignant T cells.8
Therefore, it is possible that IL-17 expression in skin lesions is
a consequence of anti-S. aureus responses by malignant and/or
nonmalignant T cells in CTCL. Since S. aureus infections are
associated with a poor prognosis, it is possible that IL-17 is
a marker of infection rather than a primary driver of disease
progression. An alternative, but not mutually exclusive,
explanation might be that IL-17 family cytokines promote
a pro-tumorigenic microenvironment in CTCL. For example,
IL-17F released by malignant T cells promotes angiogenesis
in vitro37 and IL-17A/F stimulates expression of IL-6, IL-8,
COX2/PGE2, MCP-1 and G-CSF in keratinocytes, fibroblasts,
and endothelial cells.38,39 As PGE2 is a growth factor for malig-
nant T cells,40 IL-17 cytokines may drive malignant prolifera-
tion via induction of PGE2 and other growth factors in the
microenvironment.41
S. aureus and its toxins have previously been associated with
CTCL disease progression by inducing STAT3 activation, an
oncogene implicated in the survival and proliferation of malig-
nant T cells.6,8,42 In addition, our studies suggest that the
Staphylococcal alpha-toxin further contributes to CTCL patho-
genesis by tilting the balance between malignant and nonmalig-
nant CD4+ T cells15 and by interfering with the anti-cancer
response of CD8+ T cells. The current findings support the use
of antibiotic treatment in CTCL patients and suggest a benefit of
using a combinatorial treatment approach including antibiotics
and neutralizing antibodies targeting alpha-toxin, therapies
which have previously been shown to have synergistic effects.13
In addition, the selective effect of a bacterial toxin on malignant
versus anti-cancer immune cells may also have implications for
immune therapies aimed at augmenting CD8-mediated killing
of cancer cells (reviewed in43,44) where bacterial infections are
involved. S. aureus infections are not limited to CTCL patients
and are also a matter of concern in other cancers as well as
benign skin diseases, where an effect of alpha-toxin on protective
immune cells could also play an important role.45,46
In conclusion, we provide first evidence that S. aureus-
derived alpha-toxin can effectively eliminate cytotoxic T cell-
mediated killing of malignant cells, allowing immune evasion
and continued growth of malignant CTCL cells. Thus, our find-
ings suggest a novel mechanism by which alpha-toxin-
producing S. aureus may promote disease persistence and pro-
gression in CTCL and suggests that neutralizing alpha-toxinmay
represent a promising therapeutic approach.
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